ReviewMolecules (Basel, Switzerland)2020
An Updated Review on the Synthesis and Antibacterial Activity of Molecular Hybrids and Conjugates Bearing Imidazole Moiety.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Graphitic Carbon Nitride (g-CMolecules (Basel, Switzerland) · 2026Review
- Synthesis of 2-Aryl-4-aminoquinazolines: Design, Molecular Docking, and In Vitro Assessment of Antibacterial and Cytotoxic Potential.International journal of molecular sciences · 2026Article
- Preliminary Toxicological Evaluation of Spherical Nanoparticles Containing an Imidazole Derivative (BzIm-DEA) Using the CAM Chicken Model.International journal of molecular sciences · 2026Article
- Potent Bacteriostatic Activity of a Naphthalene-2-Acyl Imidazolium Salt against Xanthomonas oryzae pv. oryzae.The plant pathology journal · 2026Article
- Synthesis and catalytic application of bimetallic-MOFs in synthesis of new class of phenylnicotinonitriles.RSC advances · 2025Article
- Novel Metronidazole Conjugates as Antimicrobial Agents.Drug development research · 2025Article
- Ferrocene-Based Hybrid Drugs as Potential Anticancer and Antibacterial Therapeutic Agents for Incorporation into Nanocarriers: In Silico, In Vitro, Molecular Docking Evaluations.Pharmaceutics · 2025Article
- Facile synthesis, antimicrobial activity, and molecular docking analysis of 8-hydroxyquinoline-4-thiazolidinone hybrids.Future medicinal chemistry · 2025Article
- Synthesis of Hybrid Molecules with Imidazole-1,3,4-thiadiazole Core and Evaluation of Biological Activity onMolecules (Basel, Switzerland) · 2024Article
- Synthesis, Crystal Structures, Genotoxicity, and Antifungal and Antibacterial Studies of Ni(II) and Cd(II) Pyrazole Amide Coordination Complexes.Molecules (Basel, Switzerland) · 2024Article
- Article
- Novel 2-Acetamido-2-ylidene-4-imidazole Derivatives (El-Saghier Reaction): Green Synthesis, Biological Assessment, and Molecular Docking.ACS omega · 2023Article
- Article
- Synthesis and characterization of low surface energy thermoplastic polyurethane elastomers based on polydimethylsiloxane.RSC advances · 2023Article
- Synthesis and Evaluation on the Fungicidal Activity of S-Alkyl Substituted Thioglycolurils.International journal of molecular sciences · 2023Article
- Antibacterial activities of plant leaf extracts against multi-antibiotic resistant Staphylococcus aureus associated with skin and soft tissue infections.BMC complementary medicine and therapies · 2022Article
- Novel Small-Molecule Hybrid-Antibacterial Agents againstMolecules (Basel, Switzerland) · 2021Article
- Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates.Frontiers in chemistry · 2021Review
- Pathogenic Characteristics and Risk Factors for ESKAPE Pathogens Infection in Burn Patients.Infection and drug resistance · 2021Article
- Imidazole and Imidazolium Antibacterial Drugs Derived from Amino Acids.Pharmaceuticals (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid growth of serious infections caused by antibiotic resistant bacteria, especially the nosocomial ESKAPE pathogens, has been acknowledged by Governments and scientists and is one of the world's major health problems. Various strategies have been and are currently investigated and developed to reduce and/or delay the bacterial resistance. One of these strategies regards the design and development of antimicrobial hybrids and conjugates. This unprecedented critical review, in which our continuing interest in the synthesis and evaluation of the bioactivity of imidazole derivatives is testified, aims to summarise and comment on the results obtained from the end of the 1900s until February 2020 in studies conducted by numerous international research groups on the synthesis and evaluation of the antibacterial properties of imidazole-based molecular hybrids and conjugates in which the pharmacophoric constituents of these compounds are directly covalently linked or connected through a linker or spacer. In this review, significant attention was paid to summarise the strategies used to overcome the antibiotic resistance of pathogens whose infections are difficult to treat with conventional antibiotics. However, it does not include literature data on the synthesis and evaluation of the bioactivity of hybrids and conjugates in which an imidazole moiety is fused with a carbo- or heterocyclic subunit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.